+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Global Non-small Cell Lung Cancer Therapeutics Market: Favorable Government Policies Augmenting Demand, finds TMR

Posted on Dec 19, 2016

Genentech, a Roche company, dominates the global non-small cell lung cancer (NSCLC) therapeutics market, individually accounting for more than 36% of the market shares in 2014. Transparency Market Research finds that the market is characterized by the presence of both generic and branded companies, and positions Eli Lilly and Company as the second-most prominent player. Rest of the market is fragmented, and highly competitive, with a few formidable players including AstraZeneca plc, Celgene Corporation, Bristol-Myers Squibb, Novartis AG, Pfizer, Inc., Boehringer Ingelheim, and Sun Pharmaceutical Industries Ltd. 

Rated as the most dreaded of all types of lung cancer, new NSCLC drugs are readily given approval by regulatory bodies, and research and development is encouraged. This factor is leading to rapid innovation, which will eventually decide the leader of the market in future. The global market for non-small cell lung cancer therapeutics was valued at US$4.9 bn in 2014. Rising at a robust CAGR of 12.10% during the forecast period of 2015 to 2023, the valuation is estimated to reach a US$15.1 bn mark by the end of 2023. 

Zykadia Projected for Strongest Growth Rate

The global NSCLC market has been bifurcated on the basis of drugs class, pipeline stage, and geography. By drug class, the market is categorized into angiogenesis inhibitor, epidermal growth factor receptor (EGFR) blocker, kinase inhibitor, folate antimetabolites, microtubule stabilizer, and PD-1/PD-L1 inhibitors. In 2014, the segment of angiogenesis inhibitor dominated the demand, owing to reasons such as high efficacy, targeted therapies, and increasing demand from country-wide markets of the U.S. and Japan. The report rates Zykadia, a sub-segment of kinase inhibitor, for the strongest CAGR during the forecast period, followed by Opdivo, a sub-segment of PD-1/PD-L1 inhibitors. 

Geographically, the report studies the regional non-small cell lung cancer therapeutics markets in North America, Europe, Asia Pacific, and Rest of the World. North America dominated the demand in 2014 due to the presence of robust healthcare infrastructure and an efficient government system in the U.S. and Canada. However, Asia Pacific is expected to boost the demand at a stronger CAGR during the forecast period due to vast population, growing awareness about NSCLC, and increased governmental projects related to lung, cancer, and tobacco. 

Wide Patient Pool Augmenting Demand

In recent past, the demand for NSCLC therapeutics has surged significantly, and has become the most common type of lung cancer. According to American lung cancer society, about two out of three people diagnosed with lung cancer are 65 years or older. According to the author of the report, “This increasing pool of patients and rising geriatric population across the globe are the primary drivers in the global market for non-small cell lung cancer therapeutics.” Additionally, the author adds that approval of some of the late-stage pipeline products, such as necitumumab and onartuzumab will further fuel the growth rate in positive direction. The report also observes that drugs used in the NSCLC treatment range from regular regimens to targeted therapies, and concurrently are based on simple chemistries to advanced complex protein. As the awareness about the prevalence of lung cancer multiplies, several governments across the globe are offering favorable policies for the players in the market. This factor is also expected to fuel the demand during the forecast period. 

The information presented in this review is based on a Transparency Market Research report, titled, “Non-small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.” 

Key Segments of the Global Non-small Cell Lung Cancer Therapeutics Market

By Drug Class

  • Angiogenesis Inhibitor
    • Avastin (bevacizumab)
    • Cyramza (Ramucirumab)
  • Epidermal Growth Factor Receptor Blocker
    • Tarceva (erlotinib)
    • Gilotrif (afatinib)
    • Iressa (gefitinib)
  • Kinase Inhibitor
    • Xalkori (crizotinib)
    • Zykadia (ceritinib)
  • Microtubule Stabilizer
    • Abraxane (paclitaxel protein bound)
    • Docetaxel
  • Folate Antimetabolites
    • Alimta (pemetrexed)
  • PD-1/ PD-L1 Inhibitor
    • Opdivo (nivolumab)
    • Keytruda (pembrolizumab)

By Pipeline

  • Early Stage (Phase I and II)
  • Late Stage (Phase III)
  • Avelumab - Pfizer Inc.
  • MPDL3280A - Roche
  • MEDI4736 - AstraZeneca
  • Abemaciclib - Eli Lilly and Company
  • Others 

Major regions analyzed under this research report are:

  • Europe
  • North America
  • Asia Pacific
  • Rest of the World 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Back To Top